Quantcast

Latest Gonadotropin-releasing hormone Stories

2011-05-11 12:50:38

Gonadotrophin-releasing hormone antagonists as effective as agonists with fewer serious harmful effects With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women...

2011-05-11 07:36:23

(Ivanhoe Newswire) -- Giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists, according to a new study. Previous research had concluded that women who used antagonists tended to have lower birth-rates than those using agonists. This is important because the research also showed that GnRH antagonists can halve the risk of over-stimulating the ovaries compared with GnRH agonists, as well as halving the number of women who...

2010-11-29 14:47:33

A hormone responsible for the onset of puberty can end up stuck in the wrong part of the body if the nerve pathways responsible for its transport to the brain fail to develop properly, according to research funded by the Biotechnology and Biological Sciences Research Council (BBSRC). By tracking how nerve cells responsible for regulating sexual reproduction in mice find their way from their birth place in the foetal nose to their site of action in the adult brain, scientists from University...

2010-06-01 15:30:00

SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr. Judd Moul, Chief of the Division of Urology at Duke University Health Science Center. Dr. Moul was joined at the...

2010-05-03 10:37:00

Preliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists SILVER SPRING, Md., May 3 /PRNewswire-USNewswire/ -- Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing...

2010-03-11 15:15:00

MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer. With an anticipated May launch, TRELSTAR® 22.5 mg is the first and only...

2009-12-23 14:12:21

Previous work in birds and sheep shows a wealth of clinical possibilities Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases. The hormone, gonadotropin inhibitory hormone (GnIH), has the opposite effect from gonadotropin releasing hormone, a key...

2009-12-04 08:07:00

BETHESDA, Md., Dec. 4 /PRNewswire/ -- Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment. Prostate cancer patients who received FIRMAGON 240/80 mg/month had a recurrence rate of...

2009-11-20 07:07:00

WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program....

2009-08-04 07:55:00

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix,...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related